Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer (mCRC) program continues to show our lead candidate onvansertib demonstrates an objective...
Source: prnewswire.com